TORONTO--(BUSINESS WIRE)--Nov 1, 2023--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce the completion of the ...
SAN DIEGO--(BUSINESS WIRE)--Nov 1, 2023--Calidi Biotherapeutics, Inc. (NYSE American: CLDI or 鈥淐alidi鈥�), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced two key promotions from the clinical leadership team and the appointment ...
RAHWAY, N.J.--(BUSINESS WIRE)--Nov 1, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck蘑菇视频 anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the ...
BOSTON--(BUSINESS WIRE)--Nov 1, 2023--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the ...
RAHWAY, N.J.--(BUSINESS WIRE)--Nov 1, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck蘑菇视频 anti-PD-1 therapy, met its key secondary endpoint of overall survival (OS), for the adjuvant ...
SOMERVILLE, Mass., & BUFFALO, N.Y.--(BUSINESS WIRE)--Nov 1, 2023--Generate:Biomedicines and Roswell Park Comprehensive Cancer Center today announced a strategic collaboration to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up ...